SCHEMBL3025733

SCHEMBL3025733

CC(C)(C)OC(=O)C(CN)c1cccc(OCc2ccccc2)c1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
ALOX5 P09917 1/20 0.48
MAOB P27338 3/20 0.48
LTA4H P09960 2/20 0.47
NR4A2 P43354 2/20 0.47
MEN1 O00255 1/20 0.46
EPOR P19235 1/20 0.44
PDK1 Q15118 1/20 0.44
PDK2 Q15119 1/20 0.44
PDK3 Q15120 1/20 0.44
PDK4 Q16654 1/20 0.44
SPHK2 Q9NRA0 1/20 0.44
NR4A1 P22736 1/20 0.44
NR4A3 Q92570 1/20 0.44
ACACB O00763 1/20 0.43
SMPD1 P17405 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30854869 1.00 KMT2A (0.55) KMT2ASMN1; SMN2ALOX5MAOBLTA4H
SCHEMBL21656313 0.83 L3MBTL1 (0.50)
SCHEMBL30854879 0.82 CACNA1B (0.45) SMN1; SMN2ALOX5ACACBSMPD1
SCHEMBL3026700 0.82 CACNA1B (0.45) SMN1; SMN2ALOX5ACACBSMPD1
SCHEMBL14699488 0.81 KMT2A (0.55) KMT2ASMN1; SMN2ALOX5MAOBLTA4H
SCHEMBL14699489 0.81 KMT2A (0.55) KMT2ASMN1; SMN2ALOX5MAOBLTA4H
SCHEMBL15268712 0.81 SLC6A2 (0.42) KMT2ASMN1; SMN2MEN1
SCHEMBL3028651 0.80 ROCK2 (0.42)
SCHEMBL30854880 0.80 ROCK2 (0.42)
SCHEMBL31724359 0.79 SYK (0.51) KMT2ASMN1; SMN2ALOX5MAOBLTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155663-B1 SUBSTITUTED 2-[2-(PHENYL)ETHYLAMINO]ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS NEWRON PHARM SPA (IT) 2017-11-29 EP disclosed
US-9603832-B2 Substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives and their use as sodium and/or calcium channel modulators NEWRON PHARMACEUTICALS S.P.A. (IT) 2017-03-28 US disclosed
US-9585869-B2 Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators NEWRON PHARMACEUTICALS, S.P.A. (IT) 2017-03-07 US disclosed
US-9474737-B2 Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators NEWRON PHARMACEUTICALS S.P.A. (IT) 2016-10-25 US disclosed
US-9474739-B2 Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators NEWRON PHARMACEUTICALS S.P.A. (IT) 2016-10-25 US disclosed
US-9474738-B2 Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators NEWRON PHARMACEUTICALS S.P.A. (IT) 2016-10-25 US disclosed
US-9248116-B2 Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators NEWRON PHARMACEUTICALS S.P.A. (IT) 2016-02-02 US disclosed
US-20150157601-A1 SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS NEWRON PHARMACEUTICALS S.P.A. (IT) 2015-06-11 US disclosed
US-20150157598-A1 SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS NEWRON PHARMACEUTICALS S.P.A. (IT) 2015-06-11 US disclosed
US-20150157600-A1 SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS NEWRON PHARMACEUTICALS S.P.A. (IT) 2015-06-11 US disclosed
US-20150157602-A1 SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS NEWRON PHARMACEUTICALS S.P.A. (IT) 2015-06-11 US disclosed
US-20150157599-A1 SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS NEWRON PHARMACEUTICALS S.P.A. (IT) 2015-06-11 US disclosed
US-9051240-B2 Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators NEWRON PHARMACEUTICALS S.P.A. (IT) 2015-06-09 US disclosed
US-20130289122-A1 SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS NEWRON PHARMACEUTICALS S.P.A (IT) 2013-10-31 US disclosed
US-20130274249-A1 SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS NEWRON PHARMACEUTICALS S.P.A (IT) 2013-10-17 US disclosed
US-8519000-B2 Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators NEWRON PHARMACEUTICALS S.P.A. (IT) 2013-08-27 US disclosed
US-20100210631-A1 SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS NEWRON PHARMACEUTICALS S.P.A. (IT) 2010-08-19 US disclosed
EP-2155663-A1 SUBSTITUTED 2- Ý2- (PHENYL) ETHYLAMINO¨ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS Newron Pharmaceuticals S.p.A. (IT) 2010-02-24 EP disclosed
WO-2008151702-A1 SUBSTITUTED 2- [2- (PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS NEWRON PHARMACEUTICALS S.P.A. (IT) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130274249-A1 SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS CACNA1A, CACNA1B, SARAF KMT2A 686/4885SMN1; SMN2 678/4885ALOX5 402/4885
US-20150157601-A1 SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS CACNA1A, CACNA1E, CACNA1S KMT2A 1016/4885SMN1; SMN2 918/4885ALOX5 988/4885
US-20150157598-A1 SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS CACNA1A, CACNA1E, CACNA1S KMT2A 1016/4885SMN1; SMN2 918/4885ALOX5 988/4885
US-20100210631-A1 SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS CACNA1A, CACNA1B, SARAF KMT2A 698/4885SMN1; SMN2 699/4885ALOX5 416/4885
US-20130289122-A1 SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS CACNA1A, CACNA1B, SARAF KMT2A 686/4885SMN1; SMN2 678/4885ALOX5 402/4885
US-20150157600-A1 SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS CACNA1A, CACNA1E, CACNA1S KMT2A 1016/4885SMN1; SMN2 918/4885ALOX5 988/4885
US-20150157602-A1 SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS CACNA1A, CACNA1E, CACNA1S KMT2A 1016/4885SMN1; SMN2 918/4885ALOX5 988/4885
US-20150157599-A1 SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS CACNA1A, CACNA1E, CACNA1S KMT2A 1016/4885SMN1; SMN2 918/4885ALOX5 988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.